Global Multiple Myeloma Therapeutics Market
According to the report " Multiple Myeloma Therapeutics Market ", published by Market Data Forecast , the global market is projected to reach USD 9.1 Billion by 2021 , at a CAGR of 4.8 % from 2016 to 2021 .
Multiple myeloma remains comparatively rare , it is a deceptive disease and patients typically deplete treatment alternatives . Myeloma and MGUS are twice as common in blacks paralleled with whites and marginally more common in males than females . The Multiple Myeloma ( MM ) market is presently dominated by Velcade and Revlimid , and the market is set to experience considerable growth between 2016 and 2021 .
Expanding indications of existing drugs , emergence of new and promising drugs , increasing incidence of multiple myeloma and increasing use of drugs already on the market are fuelling growth of the market . Factors such as varied therapeutic areas , rising investment in research and development for new therapies , increasing demand and extensive off-label use of IG are some of the foremost factors contributing to the growth of the multiple myeloma therapeutics market .
The Global Multiple Myeloma Therapeutics Market is segmented by Treatment Type , Drug Type and Geography
1 . By Treatment Type : � Chemotherapy
• Anthracycline antibiotic a ) Melphalan ( Alkeran ) b ) Liposomal doxorubicin ( Doxil )
• Alkylating agent a ) Doxorubicin ( Adriamycin ) b ) Cyclophosphamide ( Neosar ) c ) Vincristine ( Oncovin ) d ) Carmustine ( BiCNU )
� Targeted therapy
• Proteasome inhibitor a ) Bortezomib ( Velcade ) b ) Carfilzomib ( Kyprolis )
2 . By Drug Type
� Corticosteroids
• Dexamethasone ( Decadron )
• Prednisone ( Deltasone / Orasone )
� Immunomodulatory agents
• Thalidomide ( Thalomid )
• Lenalidomide ( Revlimid )
• Arsenic trioxide ( Trisenox )
• Plerixafor ( Mozobil )
3 . By Geography : � North America � Europe
+ 1 888-702-9626 | www . marketdataforecast . com | contact @ marketdataforecast . com